Search research articles
Contact Us
Filters
Showing results (61-70 of 83) with videos related to
Page
of 9
Sort By:
Blood
|
June 2, 2011
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
John D Shaughnessy, Pingping Qu, Saad Usmani, et al.
Cancer Science
|
February 26, 2018
Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Shinsuke Iida, Masashi Wakabayashi, Kunihiro Tsukasaki, et al.
Clinical Hematology International
|
August 11, 2025
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group
Wenming Chen, Zhen Cai, Chor Sang Chim, et al.
Cell Death Discovery
|
January 28, 2024
ARK5 enhances cell survival associated with mitochondrial morphological dynamics from fusion to fission in human multiple myeloma cells
Sivasundaram Karnan, Ichiro Hanamura, Akinobu Ota, et al.
Clinical Hematology International
|
May 8, 2026
Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group
Wenming Chen, Zhen Cai, Chor Sang Chim, et al.
Genes, Chromosomes & Cancer
|
October 4, 2011
Establishment of a novel human myeloid leukemia cell line, AMU-AML1, carrying t(12;22)(p13;q11) without chimeric MN1-TEL and with high expression of MN1
Mayuko Gotou, Ichiro Hanamura, Hisao Nagoshi, et al.
International Journal of Hematology
|
June 14, 2022
Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myeloma
Satsuki Murakami, Masaki Ri, Masato Ito, et al.
Cell Death & Disease
|
March 1, 2026
Targeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma
Sivasundaram Karnan, Akinobu Ota, Muhammad Nazmul Hasan, et al.
FEBS Open Bio
|
December 8, 2018
Establishment and characterization of a novel vincristine-resistant diffuse large B-cell lymphoma cell line containing the 8q24 homogeneously staining region
Shohei Mizuno, Ichiro Hanamura, Akinobu Ota, et al.
Cell Death & Disease
|
June 23, 2026
Nintedanib inhibits the VEGFR-ERK signaling pathway in human KRAS-mutated cancer cells
Sivasundaram Karnan, Akinobu Ota, Muhammad Nazmul Hasan, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 83) with videos related to
Sort By:
Page
of 9
Blood
|
June 2, 2011
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
John D Shaughnessy, Pingping Qu, Saad Usmani, et al.
Cancer Science
|
February 26, 2018
Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Shinsuke Iida, Masashi Wakabayashi, Kunihiro Tsukasaki, et al.
Clinical Hematology International
|
August 11, 2025
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group
Wenming Chen, Zhen Cai, Chor Sang Chim, et al.
Cell Death Discovery
|
January 28, 2024
ARK5 enhances cell survival associated with mitochondrial morphological dynamics from fusion to fission in human multiple myeloma cells
Sivasundaram Karnan, Ichiro Hanamura, Akinobu Ota, et al.
Clinical Hematology International
|
May 8, 2026
Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group
Wenming Chen, Zhen Cai, Chor Sang Chim, et al.
Genes, Chromosomes & Cancer
|
October 4, 2011
Establishment of a novel human myeloid leukemia cell line, AMU-AML1, carrying t(12;22)(p13;q11) without chimeric MN1-TEL and with high expression of MN1
Mayuko Gotou, Ichiro Hanamura, Hisao Nagoshi, et al.
International Journal of Hematology
|
June 14, 2022
Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myeloma
Satsuki Murakami, Masaki Ri, Masato Ito, et al.
Cell Death & Disease
|
March 1, 2026
Targeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma
Sivasundaram Karnan, Akinobu Ota, Muhammad Nazmul Hasan, et al.
FEBS Open Bio
|
December 8, 2018
Establishment and characterization of a novel vincristine-resistant diffuse large B-cell lymphoma cell line containing the 8q24 homogeneously staining region
Shohei Mizuno, Ichiro Hanamura, Akinobu Ota, et al.
Cell Death & Disease
|
June 23, 2026
Nintedanib inhibits the VEGFR-ERK signaling pathway in human KRAS-mutated cancer cells
Sivasundaram Karnan, Akinobu Ota, Muhammad Nazmul Hasan, et al.
Page
of 9